118 related articles for article (PubMed ID: 38098046)
1. Effectiveness and safety of different doses of febuxostat compared with allopurinol in the treatment of hyperuricemia: a meta-analysis of randomized controlled trials.
Xie H; Hu N; Pan T; Wu JC; Yu M; Wang DC
BMC Pharmacol Toxicol; 2023 Dec; 24(1):79. PubMed ID: 38098046
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta-analysis.
Deng JH; Lai PH; Xie LS; Qiu SS; Qiu DS; Zhang JX
Clin Transl Sci; 2024 Mar; 17(3):e13757. PubMed ID: 38488426
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the efficacy and safety of benzbromarone and febuxostat in gout and hyperuricemia: a systematic review and meta-analysis.
Wu F; Chen L; Du Y
Clin Rheumatol; 2024 May; 43(5):1745-1754. PubMed ID: 38492092
[TBL] [Abstract][Full Text] [Related]
4. Febuxostat provides renoprotection in patients with hyperuricemia or gout: a systematic review and meta-analysis of randomized controlled trials.
Yang XH; Zhang BL; Cheng Y; Fu SK; Jin HM
Ann Med; 2024 Dec; 56(1):2332956. PubMed ID: 38738384
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy of febuxostat vs. benzbromarone in the treatment of gout: a meta-analysis in Chinese gout patients.
Yan CQ; Liang C; Lan ZR; Su C; Xiong SY; Yang YX; Chen JM; Tang SL; Huang JS; Zhang ZH; Luo MJ; Xiao ZH
Eur Rev Med Pharmacol Sci; 2023 Dec; 27(24):11988-12003. PubMed ID: 38164861
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the therapeutic effects of febuxostat combined with a low-purine diet and allopurinol combined with a low-purine diet on the improvement of gout patients.
Chen X; Ye T; Dai Y; Li P; Zhao X; Yu Y; Wang X; Jiao X; Shen N
Int J Rheum Dis; 2024 May; 27(5):e15165. PubMed ID: 38769820
[TBL] [Abstract][Full Text] [Related]
7. Comparison of clinical and economic evaluation between selected generic and original febuxostat tablets in Chinese gout patients with hyperuricemia: A real-world multicenter retrospective study.
Si X; Huang L; Ding Q; Zhang W; Zhao R; Ai C; An Z; Liu G; Zhang C; Zhong X; Feng Y
Medicine (Baltimore); 2024 Jan; 103(4):e37081. PubMed ID: 38277524
[TBL] [Abstract][Full Text] [Related]
8. Impacts of Febuxostat on Cerebral and Cardiovascular Events in Elderly Patients with Hyperuricemia: Post Hoc Analysis of a Randomized Controlled Trial.
Sugawara M; Kojima S; Hisatome I; Matsui K; Uchiyama K; Yokota N; Tokutake E; Wakasa Y; Hiramitsu S; Waki M; Jinnouchi H; Kakuda H; Hayashi T; Kawai N; Mori H; Tsujita K; Ohya Y; Kimura K; Saito Y; Ogawa H;
Clin Pharmacol Ther; 2024 Jun; 115(6):1358-1364. PubMed ID: 38389505
[TBL] [Abstract][Full Text] [Related]
9. Urate-Lowering Drugs and Muscle Injury: A Systematic Review and Network Meta-Analysis.
Mitsuboshi S; Morizumi M; Kotake K; Kaseda R; Narita I
J Clin Pharmacol; 2024 Mar; 64(3):288-299. PubMed ID: 37840156
[TBL] [Abstract][Full Text] [Related]
10. Febuxostat in the management of hyperuricemia and chronic gout: a review.
Hu M; Tomlinson B
Ther Clin Risk Manag; 2008 Dec; 4(6):1209-20. PubMed ID: 19337428
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of febuxostat in patients with hyperuricemia and gout.
Garcia-Valladares I; Khan T; Espinoza LR
Ther Adv Musculoskelet Dis; 2011 Oct; 3(5):245-53. PubMed ID: 22870483
[TBL] [Abstract][Full Text] [Related]
12. Impact of Hyperuricemia and Urate-Lowering Agents on Cardiovascular Diseases.
Sosa F; Shaban M; Lopez J; Duarte GJ; Jain S; Khizar A; Vittorio T; Mishra R; Rodriguez Guerra M
Clin Med Insights Cardiol; 2024; 18():11795468241239542. PubMed ID: 38529322
[TBL] [Abstract][Full Text] [Related]
13. Clinical Effect of the Guizhi Shaoyao Zhimu Decoction in the Treatment of Hyperuricemia.
Yang Q; Zhang J; Li J
Biomed Res Int; 2022; 2022():5186210. PubMed ID: 36060146
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of Hyperuricemia and the Use of Allopurinol in Older Poles-Results from a Population-Based PolSenior Study.
Winder M; Owczarek AJ; Mossakowska M; Broczek K; Grodzicki T; Wierucki Ł; Chudek J
Int J Environ Res Public Health; 2021 Jan; 18(2):. PubMed ID: 33419128
[TBL] [Abstract][Full Text] [Related]
15. Two cases report of febuxostat-induced acute liver injury: acute heart failure as a probable risk factor?
Zhu B; Liu B; Tang G; Jin P; Liu D
Drug Chem Toxicol; 2024 Jan; 47(1):55-59. PubMed ID: 36789513
[TBL] [Abstract][Full Text] [Related]
16. Relationship between hyperuricemia and the risk of cardiovascular events and chronic kidney disease in both the general population and hypertensive patients: A systematic review and meta-analysis.
Zheng L; Zhu Y; Ma Y; Zhang H; Zhao H; Zhang Y; Yang Z; Liu Y
Int J Cardiol; 2024 Mar; 399():131779. PubMed ID: 38218247
[TBL] [Abstract][Full Text] [Related]
17. Estimation of the spatial pattern of gout prevalence across China by wastewater-based epidemiology.
Zhou X; Liu K; Shi C; Zhang M; Liu S; Hou C; Di B
Sci Total Environ; 2024 May; 924():171565. PubMed ID: 38461984
[TBL] [Abstract][Full Text] [Related]
18. Effect of uric acid reduction on chronic kidney disease. Systematic review and meta-analysis.
Casanova AG; Morales AI; Vicente-Vicente L; López-Hernández FJ
Front Pharmacol; 2024; 15():1373258. PubMed ID: 38601468
[TBL] [Abstract][Full Text] [Related]
19. Comment on "A Randomized, Double-Blind, Non-inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects with or Without Gout".
van Leeuwen KDB; Bohnen AM
Rheumatol Ther; 2020 Mar; 7(1):215-216. PubMed ID: 31823214
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
